Researchers Submit Patent Application, "TMEM173 saRNA Compositions and Methods of Use", for Approval (USPTO 20240175033).

MiNA Therapeutics Limited has submitted a patent application for TMEM173 saRNA compositions and methods of use. The patent application describes the use of synthetic isolated small activating RNAs (saRNAs) to up-regulate the expression of the TMEM173 gene, which is involved in immune signaling pathways. The saRNAs are designed to target specific sequences of the TMEM173 gene and can be used to modulate immune responses and potentially treat diseases such as cancer. The patent application provides details on the saRNA compositions, pharmaceutical compositions, and methods of administration. MiNA Therapeutics Limited, based in London, United Kingdom, is the assignee of the patent. [Extracted from the article]